Sonova Holding AG (SONVY)
60.59
-0.81
(-1.32%)
USD |
OTCM |
Jun 21, 16:00
Sonova PS Ratio: 4.387 for June 21, 2024
PS Ratio Chart
Historical PS Ratio Data
| Date | Value |
|---|---|
| June 21, 2024 | 4.387 |
| June 20, 2024 | 4.446 |
| June 18, 2024 | 4.440 |
| June 17, 2024 | 4.439 |
| June 14, 2024 | 4.506 |
| June 13, 2024 | 4.587 |
| June 12, 2024 | 4.607 |
| June 11, 2024 | 4.649 |
| June 10, 2024 | 4.626 |
| June 07, 2024 | 4.650 |
| June 06, 2024 | 4.713 |
| June 05, 2024 | 4.687 |
| June 04, 2024 | 4.669 |
| June 03, 2024 | 4.562 |
| May 31, 2024 | 4.606 |
| May 30, 2024 | 4.561 |
| May 29, 2024 | 4.569 |
| May 28, 2024 | 4.595 |
| May 24, 2024 | 4.652 |
| May 23, 2024 | 4.675 |
| May 22, 2024 | 4.594 |
| May 21, 2024 | 4.472 |
| May 20, 2024 | 4.592 |
| May 17, 2024 | 4.650 |
| May 16, 2024 | 4.741 |
| Date | Value |
|---|---|
| May 15, 2024 | 4.773 |
| May 14, 2024 | 4.580 |
| May 13, 2024 | 4.263 |
| May 10, 2024 | 4.324 |
| May 09, 2024 | 4.286 |
| May 08, 2024 | 4.251 |
| May 07, 2024 | 4.256 |
| May 06, 2024 | 4.196 |
| May 03, 2024 | 4.222 |
| May 02, 2024 | 4.136 |
| May 01, 2024 | 4.058 |
| April 30, 2024 | 4.012 |
| April 29, 2024 | 4.112 |
| April 26, 2024 | 4.080 |
| April 25, 2024 | 4.002 |
| April 24, 2024 | 4.048 |
| April 23, 2024 | 4.044 |
| April 22, 2024 | 4.037 |
| April 19, 2024 | 3.93 |
| April 18, 2024 | 3.926 |
| April 17, 2024 | 3.954 |
| April 16, 2024 | 4.015 |
| April 15, 2024 | 4.043 |
| April 12, 2024 | 4.042 |
| April 11, 2024 | 4.132 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
3.298
Minimum
Mar 23 2020
9.238
Maximum
Sep 16 2021
5.351
Average
5.056
Median
PS Ratio Benchmarks
| AC Immune SA | -- |
| CRISPR Therapeutics AG | -- |
| Addex Therapeutics Ltd | 3.660 |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 41.30 |
PS Ratio Related Metrics
| PE Ratio | 26.46 |
| PEG Ratio | 13.87 |
| Price to Book Value | 6.596 |
| Price to Free Cash Flow | 25.43 |
| Price | 60.59 |
| Earnings Yield | 3.78% |
| Market Cap | 18.06B |
| PEGY Ratio | 7.570 |
| Operating PE Ratio | 23.74 |
| Normalized PE Ratio | 26.46 |